BR0011539A - Hidroxamidas de ácido 3-(arilsulfonilamino)-tetrahidropirano-3-carboxìlico - Google Patents
Hidroxamidas de ácido 3-(arilsulfonilamino)-tetrahidropirano-3-carboxìlicoInfo
- Publication number
- BR0011539A BR0011539A BR0011539-8A BR0011539A BR0011539A BR 0011539 A BR0011539 A BR 0011539A BR 0011539 A BR0011539 A BR 0011539A BR 0011539 A BR0011539 A BR 0011539A
- Authority
- BR
- Brazil
- Prior art keywords
- arylsulfonylamino
- tetrahydropyran
- carboxylic acid
- cancer
- acid hydroxamides
- Prior art date
Links
- 125000004657 aryl sulfonyl amino group Chemical group 0.000 title 1
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 abstract 2
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 abstract 1
- WEAHRLBPCANXCN-UHFFFAOYSA-N Daunomycin Natural products CCC1(O)CC(OC2CC(N)C(O)C(C)O2)c3cc4C(=O)c5c(OC)cccc5C(=O)c4c(O)c3C1 WEAHRLBPCANXCN-UHFFFAOYSA-N 0.000 abstract 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 abstract 1
- 229930012538 Paclitaxel Natural products 0.000 abstract 1
- 229940009456 adriamycin Drugs 0.000 abstract 1
- 229930013930 alkaloid Natural products 0.000 abstract 1
- 229940035676 analgesics Drugs 0.000 abstract 1
- 239000000730 antalgic agent Substances 0.000 abstract 1
- 206010003246 arthritis Diseases 0.000 abstract 1
- 238000002648 combination therapy Methods 0.000 abstract 1
- 229940111134 coxibs Drugs 0.000 abstract 1
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 abstract 1
- 231100000433 cytotoxic Toxicity 0.000 abstract 1
- 230000001472 cytotoxic effect Effects 0.000 abstract 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 abstract 1
- 229960005420 etoposide Drugs 0.000 abstract 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 abstract 1
- 201000008482 osteoarthritis Diseases 0.000 abstract 1
- 229960001592 paclitaxel Drugs 0.000 abstract 1
- 229910052697 platinum Inorganic materials 0.000 abstract 1
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Substances [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 abstract 1
- 229940063683 taxotere Drugs 0.000 abstract 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 abstract 1
- 229960004528 vincristine Drugs 0.000 abstract 1
- -1 vincristine Natural products 0.000 abstract 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D309/28—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D309/14—Nitrogen atoms not forming part of a nitro radical
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Dermatology (AREA)
- Virology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Ophthalmology & Optometry (AREA)
- Psychology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
Abstract
Patente de Invenção: " HIDROXAMIDAS DE áCIDO 3-(ARILSULFONILAMINO)-TETRAHIDROPIRANO-3-CARBOXìLICO". Composto de fórmula em que R^ 1^, R^ 2^, R^ 3^, R^ 4^ e Q são como definidos acima, são úteis para o tratamento de artrite (incluindo osteoartrite e artrite reumatóide), câncer e outras doenças. Além disso, os compostos da presente invenção podem ser utilizados em terapia combinada com drogas antiinflamatórias não-esteroidais (NAIDS's), inibidores de COX-2 e analgésicos convencionais, e em combinação com drogas citotóxicas tais como adriamicina, daunomicina, cis-piatina, etoposido, taxol, taxotere e outros alcalóides, tais como vincristina, no tratamento do câncer.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13653099P | 1999-05-28 | 1999-05-28 | |
| PCT/IB2000/000647 WO2000073295A1 (en) | 1999-05-28 | 2000-05-15 | 3-(arylsulfonylamino)-tetrahydropyran-3-carboxylic acid hydroxamides |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0011539A true BR0011539A (pt) | 2002-02-26 |
Family
ID=22473239
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0011539-8A BR0011539A (pt) | 1999-05-28 | 2000-05-15 | Hidroxamidas de ácido 3-(arilsulfonilamino)-tetrahidropirano-3-carboxìlico |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US6197810B1 (pt) |
| EP (1) | EP1181286B1 (pt) |
| JP (1) | JP3784645B2 (pt) |
| AT (1) | ATE254119T1 (pt) |
| AU (1) | AU4424000A (pt) |
| BR (1) | BR0011539A (pt) |
| CA (1) | CA2375524C (pt) |
| DE (1) | DE60006523T2 (pt) |
| DK (1) | DK1181286T3 (pt) |
| DZ (1) | DZ3046A1 (pt) |
| ES (1) | ES2208315T3 (pt) |
| GT (1) | GT200000079A (pt) |
| HN (1) | HN2000000074A (pt) |
| MA (1) | MA26738A1 (pt) |
| MX (1) | MXPA01012265A (pt) |
| PA (1) | PA8495901A1 (pt) |
| PE (1) | PE20010170A1 (pt) |
| PT (1) | PT1181286E (pt) |
| SV (1) | SV2001000086A (pt) |
| TN (1) | TNSN00111A1 (pt) |
| UY (1) | UY26167A1 (pt) |
| WO (1) | WO2000073295A1 (pt) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040122011A1 (en) * | 1998-12-23 | 2004-06-24 | Pharmacia Corporation | Method of using a COX-2 inhibitor and a TACE inhibitors as a combination therapy |
| RU2245876C2 (ru) | 2000-03-21 | 2005-02-10 | Дзе Проктер Энд Гэмбл Компани | Производные сульфонамидов и фармацевтическая композиция на их основе |
| PL357250A1 (en) * | 2000-03-21 | 2004-07-26 | The Procter & Gamble Company | Heterocyclic side chain containing metalloprotease inhibitors |
| CA2401728A1 (en) | 2000-03-21 | 2001-09-27 | The Procter & Gamble Company | Difluorobutyric acid metalloprotease inhibitors |
| US7019376B2 (en) * | 2000-08-11 | 2006-03-28 | Reflectivity, Inc | Micromirror array device with a small pitch size |
| US20030045449A1 (en) * | 2001-08-15 | 2003-03-06 | Pfizer, Inc. | Pharmaceutical combinations for the treatment of neurodegenerative diseases |
| GB0319069D0 (en) * | 2003-08-14 | 2003-09-17 | Glaxo Group Ltd | Therapeutically useful compounds |
| US20050058611A1 (en) * | 2003-08-22 | 2005-03-17 | L'oreal | Preventing and/or combating collagen fiber degradation induced under conditions of natural exposure to sunlight |
| CA2747419C (en) * | 2009-01-12 | 2014-07-08 | Icagen, Inc. | Sulfonamide derivatives |
| JP5872552B2 (ja) | 2010-07-09 | 2016-03-01 | ファイザー・リミテッドＰｆｉｚｅｒ Ｌｉｍｉｔｅｄ | 化学化合物 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5455258A (en) * | 1993-01-06 | 1995-10-03 | Ciba-Geigy Corporation | Arylsulfonamido-substituted hydroxamic acids |
| HUP0000852A2 (hu) | 1997-02-03 | 2001-05-28 | Pfizer Products Inc. | Aril-szulfonil-amino-hidroxámsav-származékok, valamint e vegyületeket tartalmazó gyógyászati készítmények |
| PA8469501A1 (es) * | 1998-04-10 | 2000-09-29 | Pfizer Prod Inc | Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico |
-
2000
- 2000-05-15 BR BR0011539-8A patent/BR0011539A/pt not_active IP Right Cessation
- 2000-05-15 EP EP00925520A patent/EP1181286B1/en not_active Expired - Lifetime
- 2000-05-15 AT AT00925520T patent/ATE254119T1/de not_active IP Right Cessation
- 2000-05-15 HN HN2000000074A patent/HN2000000074A/es unknown
- 2000-05-15 WO PCT/IB2000/000647 patent/WO2000073295A1/en not_active Ceased
- 2000-05-15 CA CA002375524A patent/CA2375524C/en not_active Expired - Fee Related
- 2000-05-15 AU AU44240/00A patent/AU4424000A/en not_active Abandoned
- 2000-05-15 ES ES00925520T patent/ES2208315T3/es not_active Expired - Lifetime
- 2000-05-15 DE DE60006523T patent/DE60006523T2/de not_active Expired - Fee Related
- 2000-05-15 MX MXPA01012265A patent/MXPA01012265A/es active IP Right Grant
- 2000-05-15 JP JP2000621361A patent/JP3784645B2/ja not_active Expired - Fee Related
- 2000-05-15 DK DK00925520T patent/DK1181286T3/da active
- 2000-05-15 PT PT00925520T patent/PT1181286E/pt unknown
- 2000-05-19 PA PA20008495901A patent/PA8495901A1/es unknown
- 2000-05-24 TN TNTNSN00111A patent/TNSN00111A1/fr unknown
- 2000-05-24 DZ DZ000090A patent/DZ3046A1/xx active
- 2000-05-24 MA MA25988A patent/MA26738A1/fr unknown
- 2000-05-25 GT GT200000079A patent/GT200000079A/es unknown
- 2000-05-26 UY UY26167A patent/UY26167A1/es not_active Application Discontinuation
- 2000-05-26 US US09/579,059 patent/US6197810B1/en not_active Expired - Fee Related
- 2000-05-26 SV SV2000000086A patent/SV2001000086A/es not_active Application Discontinuation
- 2000-05-26 PE PE2000000507A patent/PE20010170A1/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| EP1181286A1 (en) | 2002-02-27 |
| CA2375524C (en) | 2006-11-28 |
| DE60006523D1 (de) | 2003-12-18 |
| UY26167A1 (es) | 2000-12-29 |
| JP3784645B2 (ja) | 2006-06-14 |
| ATE254119T1 (de) | 2003-11-15 |
| JP2003500485A (ja) | 2003-01-07 |
| CA2375524A1 (en) | 2000-12-07 |
| US6197810B1 (en) | 2001-03-06 |
| DK1181286T3 (da) | 2004-02-16 |
| PE20010170A1 (es) | 2001-02-27 |
| MXPA01012265A (es) | 2002-07-30 |
| WO2000073295A1 (en) | 2000-12-07 |
| PA8495901A1 (es) | 2002-08-26 |
| SV2001000086A (es) | 2001-11-08 |
| HN2000000074A (es) | 2001-02-02 |
| TNSN00111A1 (fr) | 2002-05-30 |
| EP1181286B1 (en) | 2003-11-12 |
| AU4424000A (en) | 2000-12-18 |
| MA26738A1 (fr) | 2004-12-20 |
| DE60006523T2 (de) | 2004-08-12 |
| ES2208315T3 (es) | 2004-06-16 |
| DZ3046A1 (fr) | 2004-03-27 |
| PT1181286E (pt) | 2004-02-27 |
| GT200000079A (es) | 2001-11-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR9912944A (pt) | Inibidores de tace | |
| YU5201A (sh) | Derivati hidroksipipekolathidroksamske kiseline kao inhibitori mmp | |
| MY121754A (en) | Arylsulfonylamino hydroxamic acid derivatives | |
| NO990821L (no) | Arylsulfonylamino-hydroksaminsyre-derivater | |
| CA2342271A1 (en) | Gem substituted hydroxamic acids | |
| BR0207760A (pt) | Composição farmacêutica, uso da mesma, métodos para o tratamento de dor e de inflamação, e, processo para a preparação de uma composição | |
| DK1181286T3 (da) | 3-(arylsulfonylamino)-tetrahydropyran-3-carboxylsyre hydroxamider | |
| ATE251618T1 (de) | 3-(arylsulfonylamino)-tetrahydrofuran-3- carbonsäure-hydroxamide | |
| ECSP003494A (es) | Hidroxiamidas de acidos 3- ( arilsulfonilamino)-tetrahidropiran-3-carboxilicos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 8O E 9O ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 DA RPI 2008 DE 30/06/2009. |